除细胞减灭术和腹腔热灌注化疗外，用于结直肠腹膜转移的全身治疗：临床研究和转化研究的最新见解
Systemic therapy in addition to cytoreduction and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: recent insights from clinical studies and translational research.
作者信息
Bakkers Checca, Simkens Geert A A M, De Hingh Ignace H J T
机构信息
Department of Surgery, Catharina Cancer Institute, Eindhoven, The Netherlands.
GROW - School for Oncology and Development Biology, Maastricht University, Maastricht, The Netherlands.
出版信息
J Gastrointest Oncol. 2021 Apr;12(Suppl 1):S206-S213. doi: 10.21037/jgo-20-133.
Abstract
There is a lack of randomized or high-quality intention-to-treat cohort studies addressing the role of systemic therapy in addition to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) as part of the treatment of colorectal peritoneal metastases (PM). Therefore, the choice whether or not to treat patients with systemic therapy is currently mainly based on expert opinion. As a result, treatment with neoadjuvant and/or adjuvant systemic therapy is implemented in various ways around the world. The aim of this review was to provide an overview of recent insights with regard to the systemic treatment of PM of colorectal origin obtained from clinical studies and translational research.
摘要
目前缺乏针对全身治疗在减瘤手术和腹腔热灌注化疗（CRS-HIPEC）之外作为结直肠腹膜转移（PM）治疗一部分的作用的随机或高质量意向性队列研究。因此，目前是否对患者进行全身治疗的选择主要基于专家意见。结果，新辅助和/或辅助全身治疗在世界各地以各种方式实施。本综述的目的是概述从临床研究和转化研究中获得的关于结直肠来源PM全身治疗的最新见解。
相似文献
1
Systemic therapy in addition to cytoreduction and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: recent insights from clinical studies and translational research.除细胞减灭术和腹腔热灌注化疗外，用于结直肠腹膜转移的全身治疗：临床研究和转化研究的最新见解
J Gastrointest Oncol. 2021 Apr;12(Suppl 1):S206-S213. doi: 10.21037/jgo-20-133.
2
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal and appendiceal peritoneal metastases - The Hong Kong experience and literature review.结直肠和阑尾腹膜转移的细胞减灭术和腹腔热灌注化疗（HIPEC）-香港经验和文献复习。
Asian J Surg. 2021 Jan;44(1):221-228. doi: 10.1016/j.asjsur.2020.05.010. Epub 2020 Jun 27.
3
Perioperative Systemic Therapy vs Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Alone for Resectable Colorectal Peritoneal Metastases: A Phase 2 Randomized Clinical Trial.可切除结直肠腹膜转移的围手术期全身治疗与单独细胞减灭术和腹腔热灌注化疗的比较：一项 2 期随机临床试验。
JAMA Surg. 2021 Aug 1;156(8):710-720. doi: 10.1001/jamasurg.2021.1642.
4
Neoadjuvant chemotherapy followed by hyperthermic intraperitoneal chemotherapy for patients with colorectal peritoneal metastasis: a retrospective study of its safety and efficacy.新辅助化疗联合腹腔热灌注化疗治疗结直肠腹膜转移患者的安全性和有效性：一项回顾性研究。
World J Surg Oncol. 2021 May 17;19(1):151. doi: 10.1186/s12957-021-02255-w.
5
Short and long-term outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for colorectal and appendiceal cancer peritoneal metastasis: Propensity score-matched comparison between laparoscopy vs. open approaches.结直肠和阑尾癌腹膜转移行细胞减灭术联合腹腔热灌注化疗的短期和长期疗效：腹腔镜与开腹手术的倾向评分匹配比较。
Surg Oncol. 2022 Aug;43:101766. doi: 10.1016/j.suronc.2022.101766. Epub 2022 Apr 8.
6
Patients with colorectal peritoneal metastases and high peritoneal cancer index may benefit from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.结直肠腹膜转移且腹膜肿瘤指数较高的患者可能从细胞减灭术和腹腔热灌注化疗中获益。
Eur J Surg Oncol. 2020 Dec;46(12):2283-2291. doi: 10.1016/j.ejso.2020.07.039. Epub 2020 Aug 5.
7
Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parallel-group, phase II-III, randomised, superiority study (CAIRO6).围手术期全身治疗联合细胞减灭术和 HIPEC 对比单纯 HIPEC upfront 细胞减灭术治疗孤立可切除结直肠腹膜转移瘤：一项多中心、开放标签、平行组、Ⅱ-Ⅲ 期、随机、优效性研究（CAIRO6）方案。
BMC Cancer. 2019 Apr 25;19(1):390. doi: 10.1186/s12885-019-5545-0.
8
Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial.细胞减灭术联合腹腔热灌注化疗与单纯细胞减灭术治疗结直肠腹膜转移瘤（PRODIGE 7）：一项多中心、随机、开放标签、3 期临床试验。
Lancet Oncol. 2021 Feb;22(2):256-266. doi: 10.1016/S1470-2045(20)30599-4. Epub 2021 Jan 18.
9
Review of management and treatment of peritoneal metastases from gastric cancer origin.胃癌源性腹膜转移的管理与治疗综述。
J Gastrointest Oncol. 2021 Apr;12(Suppl 1):S20-S29. doi: 10.21037/jgo-20-232.
10
Direct surgery with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for patients with colorectal peritoneal metastases.对结直肠腹膜转移患者进行细胞减灭术和热灌注腹腔化疗的直接手术。
Eur J Surg Oncol. 2021 Nov;47(11):2865-2872. doi: 10.1016/j.ejso.2021.05.046. Epub 2021 Jun 3.
引用本文的文献
1
Long-Term Outcomes following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis of Colorectal Origin.结直肠来源腹膜癌瘤细胞减灭术和腹腔热灌注化疗的长期结果。
Curr Oncol. 2024 Jun 25;31(7):3657-3668. doi: 10.3390/curroncol31070269.
2
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: Where do we stand?细胞减灭术和腹腔热灌注化疗治疗结直肠腹膜转移：我们处于什么位置？
Cancer. 2023 Feb 15;129(4):495-502. doi: 10.1002/cncr.34567. Epub 2022 Dec 16.
3
MicroRNA panels as diagnostic biomarkers for colorectal cancer: A systematic review and meta-analysis.微小RNA检测板作为结直肠癌的诊断生物标志物：一项系统评价和荟萃分析。
Front Med (Lausanne). 2022 Nov 7;9:915226. doi: 10.3389/fmed.2022.915226. eCollection 2022.
4
Preclinical In Vivo-Models to Investigate HIPEC; Current Methodologies and Challenges.用于研究腹腔热灌注化疗的临床前体内模型；当前方法与挑战
Cancers (Basel). 2021 Jul 8;13(14):3430. doi: 10.3390/cancers13143430.
5
The options are neoadjuvant, adjuvant, or no chemotherapy at all: further data is needed.选择包括新辅助化疗、辅助化疗或根本不进行化疗：还需要更多数据。
J Gastrointest Oncol. 2021 Apr;12(Suppl 1):S214-S215. doi: 10.21037/jgo-2020-19.
本文引用的文献
1
Diagnostic performance of imaging for the detection of peritoneal metastases: a meta-analysis.影像学检查在腹膜转移检测中的诊断性能：一项荟萃分析。
Eur Radiol. 2020 Jun;30(6):3101-3112. doi: 10.1007/s00330-019-06524-x. Epub 2020 Feb 17.
2
Prognostic Impact of BRAF and KRAS Mutation in Patients with Colorectal and Appendiceal Peritoneal Metastases Scheduled for CRS and HIPEC.结直肠癌和阑尾腹膜转移患者行 CRS 和 HIPEC 治疗前 BRAF 和 KRAS 基因突变的预后影响。
Ann Surg Oncol. 2020 Jan;27(1):293-300. doi: 10.1245/s10434-019-07452-2. Epub 2019 Sep 30.
3
Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer (COLOPEC): a multicentre, open-label, randomised trial.局部晚期结肠癌患者的辅助腹腔内热化疗（COLOPEC）：一项多中心、开放标签、随机试验。
Lancet Gastroenterol Hepatol. 2019 Oct;4(10):761-770. doi: 10.1016/S2468-1253(19)30239-0. Epub 2019 Jul 29.
4
Organoids from colorectal peritoneal metastases as a platform for improving hyperthermic intraperitoneal chemotherapy.结直肠腹膜转移来源的类器官作为提高腹腔内热化疗的平台。
Br J Surg. 2019 Sep;106(10):1404-1414. doi: 10.1002/bjs.11206. Epub 2019 Jun 14.
5
Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parallel-group, phase II-III, randomised, superiority study (CAIRO6).围手术期全身治疗联合细胞减灭术和 HIPEC 对比单纯 HIPEC upfront 细胞减灭术治疗孤立可切除结直肠腹膜转移瘤：一项多中心、开放标签、平行组、Ⅱ-Ⅲ 期、随机、优效性研究（CAIRO6）方案。
BMC Cancer. 2019 Apr 25;19(1):390. doi: 10.1186/s12885-019-5545-0.
6
Sites of Recurrence After Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Patients with Peritoneal Carcinomatosis from Colorectal and Appendiceal Adenocarcinoma: A Tertiary Center Experience.结直肠癌和阑尾腺癌腹膜转移患者行完全细胞减灭术和腹腔热灌注化疗后复发部位：一项三级中心经验。
Ann Surg Oncol. 2019 Feb;26(2):482-489. doi: 10.1245/s10434-018-6860-4. Epub 2018 Dec 11.
7
Mutations of RAS/RAF Proto-oncogenes Impair Survival After Cytoreductive Surgery and HIPEC for Peritoneal Metastasis of Colorectal Origin.RAS/RAF 原癌基因突变可损害结直肠来源腹膜转移患者细胞减灭术联合腹腔热灌注化疗后的生存
Ann Surg. 2018 Nov;268(5):845-853. doi: 10.1097/SLA.0000000000002899.
8
Perioperative Systemic Chemotherapy, Cytoreductive Surgery, and Hyperthermic Intraperitoneal Chemotherapy in Patients With Colorectal Peritoneal Metastasis: Results of the Prospective Multicenter Phase 2 COMBATAC Trial.结直肠癌腹膜转移患者的围手术期全身化疗、细胞减灭术和腹腔热灌注化疗：前瞻性多中心 2 期 COMBATAC 试验的结果。
Clin Colorectal Cancer. 2018 Dec;17(4):285-296. doi: 10.1016/j.clcc.2018.07.011. Epub 2018 Jul 31.
9
The current practice of cytoreductive surgery and HIPEC for colorectal peritoneal metastases: Results of a worldwide web-based survey of the Peritoneal Surface Oncology Group International (PSOGI).结直肠腹膜转移细胞减灭术和 HIPEC 的现状：腹膜表面肿瘤国际协会（PSOGI）全球网络调查的结果。
Eur J Surg Oncol. 2018 Dec;44(12):1942-1948. doi: 10.1016/j.ejso.2018.07.003. Epub 2018 Jul 20.
10
Major influence of postoperative complications on costs of cytoreductive surgery and HIPEC in patients with colorectal peritoneal metastases.术后并发症对结直肠腹膜转移患者的细胞减灭术和腹腔热灌注化疗成本的重大影响。
Medicine (Baltimore). 2018 Mar;97(10):e0042. doi: 10.1097/MD.0000000000010042.
Zotero 插件